Zero Fluoroscopy Radiofrequency Slow‐Pathway Modification for AVNRT in Patients ≤ 21 Years: A Single‐Center Cohort and Contextual Review of Literature Authors: Shailendra Upadhyay, Whitney Fairchild, Jamie Bopp, Cesar Igor Mesia Published: 2026 ABSTRACT ABSTRACTBackgroundAtrioventricular nodal reentrant tachycardia (AVNRT) is a common supraventricular tachycardia in children and is routinely treated with catheter‐based slow‐pathway ablation. Procedural safety and radiation exposure reduction are paramount in the pediatric age group, which can be accomplished with 3D electroanatomic (EAM) mapping systems.ObjectivesEvaluation of zero‐fluoroscopy radiofrequency (RF) slow‐pathway ablation outcomes for AVNRT in patients ≤ 21 years and perform a comparative analysis with the published data on cryoablation, fluoroscopy‐guided RF ablation in children, and fluoroless RF ablation in adults.MethodsWe performed a retrospective cohort study of consecutive patients aged ≤ 21 years who underwent RF catheter ablation for AVNRT between June 2016 and September 2025 using the CARTO EAM system.ResultsThe cohort included 125 patients (71 females) with a median age of 14.9 years (range 6.0–21) and median weight of 57.4 kg (IQR 48–68). Non‐steerable long sheaths were utilized in the majority of patients. Fluoroscopy time was 0 min in all cases. Acute success was achieved in all patients, with no procedural complications. Median procedure time was 121 min (102–151). Among 117/125 patients, with follow‐up at a median duration of 36 months, there was no recurrence.ConclusionsIn this consecutive cohort of 125 patients aged ≤ 21 years, zero‐fluoroscopy RF slow‐pathway modification for AVNRT was performed with complete acute success, no major complications, and no recurrences. Our data support fluoroless RF ablation as an effective and durable strategy for AVNRT in pediatric and young adult patients at experienced centers.Keywords: AVNRT, cryoablation, electroanatomic mapping, pediatric, radiation safety, radiofrequency ablation, young adult, zero fluoroscopy Background Atrioventricular nodal reentry tachycardia (AVNRT) is the second most common type of supraventricular tachycardia (SVT) in children [1]. Catheter ablation is a cornerstone therapy for symptomatic AVNRT and is now a class I recommendation in pediatric electrophysiology guidelines when medically appropriate [2]. Ablation can be performed with either radiofrequency (RF) or cryothermal (cryo) energy. While RF is the preferred modality in adults, early experience was associated with a small risk of atrioventricular (AV) block [3, 4]. Children have a higher lifetime risk of radiation exposure; therefore, minimizing ionizing radiation exposure is a major priority in pediatric practice [5, 6]. Contemporary risk models favor a linear, no threshold relationship, reinforcing the need to reduce or eliminate fluoroscopy whenever possible [7]. Advances in three‐dimensional electroanatomic mapping (3D EAM), ultrasound‐guided vascular access, and selective intracardiac echocardiography (ICE) now allow many SVT ablations to be completed with little or no fluoroscopy. A recent meta‐analysis of more than 11 000 SVT procedures confirmed that zero or minimal fluoroscopy approaches achieve success and complication rates comparable to conventional fluoroscopic techniques, while substantially lowering radiation exposure [8]. In the pediatric age group (typically defined as age ≤ 21 years in registry analyses and quality improvement datasets), fluoroscopy‐guided RF ablation has been demonstrated to have excellent outcomes and very low incidence of AV block [5, 9]. More recent, small series have shown that zero‐fluoroscopy RF ablation is feasible in children, with high acute success and favorable safety [10, 11, 12]. The present study reports the outcomes of a consecutive single‐center cohort of patients aged ≤ 21 years who underwent zero‐fluoroscopy RF slow‐pathway modification for AVNRT. Methods Study Population and Data Collection We conducted a retrospective single‐center study with institutional review board approval; the requirement for informed consent was waived. Consecutive patients ≤ 21 years who underwent electrophysiology study and RF catheter ablation for AVNRT without fluoroscopy between June 2016 and September 2025 were included. During this period, 100% of AVNRT ablations at our institution were performed without fluoroscopy. Demographic data, antiarrhythmic medication use, procedural details, electrophysiologic findings, complications, and follow‐up information were extracted from the electronic medical record. Electrophysiologic Study and Ablation Per our institutional protocol, all antiarrhythmic medications were discontinued 72 h prior to the EP study. All the procedures were performed under general anesthesia (iso‐fluorane and occasionally propofol). Bilateral femoral venous access was obtained using anatomic landmarks or ultrasound guidance. Guidewires were advanced under real‐time visualization on the CARTO mapping system using alligator clip connections, which enable the wire to appear as a moving point on the electroanatomic map, thereby allowing sheath and catheter advancement without fluoroscopy. A three‐dimensional map of the right atrium was created with the mapping catheter (decapolar, DecaNav Biosense Webster), delineating the inferior vena cava, right atrial body, coronary sinus, and tricuspid annulus. Diagnostic catheters were then positioned using electroanatomic guidance. Reference and mapping/ablation catheters were utilized in all the patients. Procedures varied from a 3 or a 4‐catheter study based on the patient's weight of below or above 30 kg respectively. For the 3‐catheter protocol (patients < 30 kg), catheters were positioned as follows: a decapolar catheter was placed in the coronary sinus, an octapolar catheter was positioned spanning the His‐bundle region and right ventricular apex, and the ablation catheter was advanced to the target site in Koch's triangle. Only 3 venous sheaths helped avoid the overall sheath burden and vascular compromise in low weight patients. For the 4‐catheter protocol (patients ≥ 30 kg), separate catheters were placed at the His‐bundle region and right ventricular apex, in addition to the coronary sinus and ablation catheter. All catheter positions were confirmed by characteristic electrogram recordings (His potential, coronary sinus activation sequence, ventricular and atrial electrograms) with EAM, rather than fluoroscopic landmarks (Figure 1). The right panel represents the left anterior oblique (LAO) projection and the left panel the right anterior oblique (RAO) projection. Yellow dots indicate the His‐bundle recording region, serving as the superior boundary of the ablation zone. Red dots indicate sites of radiofrequency energy delivery, clustered at the basal third of Koch's triangle. The coronary sinus ostium is visible in the LAO projection as an anatomic reference landmark (inferior yellow structure). The decapolar mapping catheter (orange shaft) is shown positioned in the coronary sinus and the basal portion of the Koch's triangle. Sheaths were advanced without fluoroscopy by exchanging over a guidewire visualized on the mapping system, using alligator clip connections as previously described [10]. In the youngest and smallest patients, catheter selection (B‐curve vs. D‐curve ablation catheter) was guided by cardiac anatomy assessed on the electroanatomic map, and sheath support (SEPT) was routinely employed to help position and stabilize the catheter tip at the basal portion of Koch's triangle. In cases where initial ablation applications did not produce junctional acceleration or adequate slow‐pathway modification, the ablation catheter position was systematically adjusted under electroanatomic guidance toward the more posterior and inferior aspect of Koch's triangle. AVNRT was diagnosed using standard electrophysiologic criteria [13, 14]. Slow‐pathway modification was performed using a non‐irrigated 4‐mm tip RF ablation catheter (Navistar, Biosense Webster). Long non‐steerable sheaths (SEPT, St. Jude Medical) were used in most cases to improve catheter stability. Applications for slow‐pathway modification were performed at the basal portion of Koch's triangle using RF energy, with power titrated from 20 to 50 W and a temperature limit of 70°C. During the ablation, careful monitoring was performed by looking at junctional acceleration and any ventriculoatrial (VA) interval prolongation or VA block. Acute success was determined by no inducible AVNRT or no more than one inducible AV node echo beat. Recurrence was defined as documented supraventricular tachycardia on follow‐up. The procedural workflow is consistent with contemporary fluoroless methods relying on electrogram guidance and 3D EAM visualization, as described in systematic evidence and institutional practice reports [8]. Outcomes Definition and Follow‐Up Protocol Major complications were defined as: death, cardiac perforation or tamponade, permanent AV block (second‐ or third‐degree) requiring pacemaker implantation, stroke or systemic thromboembolism, vascular injury requiring intervention, or unplanned hospital admission beyond 24 h for a procedure‐related event. Minor complications were defined as: transient first‐degree AV block or PR interval prolongation (> 200 ms) resolving prior to discharge, vascular access site hematoma not requiring intervention, and any other event not meeting major complication criteria. During ablation, any junctional rhythm with ventriculoatrial (VA) interval prolongation or VA block led to immediate cessation of radiofrequency energy delivery. Post‐procedural 12‐lead ECGs were reviewed for PR interval changes in all patients. Recurrence was defined as documented supraventricular tachycardia on a 12‐lead ECG, ambulatory monitor, or rhythm strip at any point during follow‐up, regardless of symptoms. All the patients were seen in follow‐up at our outpatient pediatric electrophysiology clinic. The standard post‐procedural follow‐up protocol included cardiology clinic visits at approximately 2, 12, and 24 months post‐ablation, with subsequent annual visits or as clinically indicated. A 12‐lead ECG was obtained at each visit. Ambulatory monitoring (24‐h Holter monitor or event recorder) was performed if symptoms suggestive of recurrence were reported. Data regarding symptoms for palpitations or SVT were also reviewed from the available primary care or emergency room visits available in the electronic health records until the conclusion of the study period. Statistical Analysis Statistical analyses were descriptive. Continuous variables are reported as median with interquartile range (IQR) and range, where appropriate. Categorical variables are presented as counts and percentages. Given the retrospective single‐center design, no formal statistical comparison with external cohorts was performed; published data are discussed contextually in the discussion. Results Patient Characteristics A total of 125 patients underwent zero‐fluoroscopy RF slow‐pathway modification for AVNRT (Table 1). Median age was 14.9 years (range 6.0–20.6) and median weight was 57.4 kg. Seventy‐one patients (56.8%) were female. Majority had documented SVT before the procedure. Majority of the patients [80/125 (64%)] were treated with medication. Beta‐blockers were the most used medications (73 patients), other agents included: calcium channel blockers (3 patients), both (2 patients), beta blocker with Digoxin in 1 patient and beta blocker with Flecainide in 1 patient. TABLE 1Baseline characteristics (age ≤ 21 cohort, n = 125).VariableValueAge, years14.9 (12.8–17.0); range 6.0–20.6Female sex71 (56.8%)Weight, kg57.4 (47.8–68.0)Documented SVT119 (95%)On antiarrhythmic medications (among recorded)80/125 (64%)AVNRT type117/125 (94%) typical, 5/125 (4%) atypical, 2/125 (1.6%) both/indeterminate, and 1/125 (0.8%) missing classification Baseline characteristics (age ≤ 21 cohort, n = 125). Electrophysiologic Study Navistar (Biosense Webster) 4 mm RF ablation catheters were utilized in all cases (Table 2). The ablation catheter curve was determined by the weight of the patient and the cardiac anatomy; A D‐curve ablation catheter was used in 98/125 (78.0%) cases; a B‐curve catheter in 27/125 (22.0%). TABLE 2Procedural metrics and outcomes (age ≤ 21 cohort, n = 125).VariableValueFluoroscopy time0 min in all casesProcedure duration, minutes121 (102–151)RF lesions, n 8 (6–14)Junctional acceleration121/125 (97%)Acute success125/125 (100%)Residual dual AV node physiology/single echo beats5/125 (4%)Major complications0Follow‐up available117/125 (94%)Follow‐up duration, months36 (25–79)Recurrence0 Procedural metrics and outcomes (age ≤ 21 cohort, n = 125). Long non steerable sheaths (SEPT, SL1, SR2, and SRO) for stabilizing the ablation catheter were required in 122/125 patients. A SEPT sheath was used in most cases, 119/122 (98%). Typical AVNRT predominated: 117/125 (94%) typical, 5/125 (4%) atypical, 2/125 (1.6%) both/indeterminate, and 1/125 (0.8%) missing classification. Median procedure duration was 121 min (IQR 102–151), with a range of 41–425 min. The one outlier patient with 425 min had a resilient WPW syndrome as well, and that was ablated non fluoroscopically. Median tachycardia cycle length (TCL) was 299 ms (IQR 250–345), and median VA interval was 11.5 ms (IQR 3.0–22.5), consistent with the expected short VA timing in typical AVNRT. Median number of RF lesions was 8 (IQR 6–14, range 1–27), and junctional acceleration was observed in 121/125 (97%) cases. Ablation sites were classified from procedural documentation and electroanatomic map tag annotations. Among 125 patients, the predominant site of successful slow‐pathway modification was the basal third of Koch's triangle (inferior to mid‐Koch's), adjacent to or just superior to the coronary sinus ostium, in 118/125 (94.4%) patients. In 7/125 (5.6%) patients, additional applications were required in the lower portion of the mid‐Koch's region. No ablation applications were delivered at or superior to the His‐bundle recording site; His‐bundle location was tagged in all cases and served as the superior anatomic boundary for catheter positioning. This is illustrated in the figure, which shows the His‐bundle tags (yellow) and ablation sites (red) in representative RAO and LAO projections. Outcomes Acute success was noted in all patients 125/125 (100%). Residual slow‐pathway conduction without inducible AVNRT was present in one patient and single echo beats without inducible AVNRT were documented in 5/125 (4%). No patient in this cohort experienced any major complications, permanent AV block of any degree, and no patient had a persistent increase in PR interval at discharge. Recurrence and Follow‐Up Follow‐up duration was available in 117/125 (94%) cases, with a median follow‐up of 36 months (IQR 25–79, range 8–115), with no recurrence. Discussion We report a large single‐center experience of completely fluoroscopy‐free radiofrequency slow‐pathway modification for AVNRT in 125 consecutive patients aged 21 years and younger. Using the CARTO 3D electroanatomic mapping system, we achieved acute success in every case, observed no procedural complications or AV nodal injury, and documented no recurrences among the 117 patients with available follow‐up (median 36 months). Our findings can be interpreted in the context of previously published studies on zero‐fluoroscopy cryoablation in children, conventional fluoroscopy‐guided RF ablation in pediatrics, and zero‐fluoroscopy RF ablation in adults. Zero‐Fluoroscopy Cryoablation for Pediatric AVNRT Several pediatric series have shown that fluoroless cryoablation for AVNRT yields high acute success rates and low complication rates. A prior cryoablation study had demonstrated good acute success with zero fluoroscopy; however, the recurrence rates ranged between 8% and 16% that improved with experience [15]. One study of 109 patients reported 100% acute success with minimal recurrence and no permanent AV block [16]. Other single‐center reports have confirmed similar feasibility and safety when using 3D mapping [17]. Our cohort achieved comparable acute success with RF energy and showed no recurrences over a relatively long median follow‐up, although differences in monitoring intensity and follow‐up duration prevent direct head‐to‐head conclusions. RF vs. Cryoablation: Durability and Safety Considerations RF and cryoablation are both safe and highly effective for AVNRT ablation [5]. Cryoablation allows reversible testing of lesion effects, which some operators prefer in smaller children (≤ 15 kg) or near the compact AV node [2, 18]. While transient AV block during the ablation procedure is more frequently encountered with cryoablation, no long‐term AV block has been reported [19]. However, meta‐analyses and registry data indicate that RF ablation often provides greater long‐term durability with lower recurrence rates [20]. Recent data from the NCDR IMPACT registry and other multicenter reviews confirm that permanent AV block is extremely rare with either modality when performed by experienced operators [5]. Various other studies with RF ablation without fluoroscopy for AVNRT in the pediatric age group have demonstrated good outcomes and no AV block [11, 12]. A 2025 multicenter pediatric comparison further suggested that RF ablation tends to be more time‐efficient once operators gain familiarity with 3D‐guided workflows [21]. In our series, exclusive use of non‐irrigated 4‐mm tip RF catheters, guided by junctional rhythm monitoring and careful titration (20–50 W, 70°C limit), produced durable results without conduction system injury. We routinely employed long stabilizing sheaths (primarily SEPT) to enhance catheter contact and control, which likely contributed to both safety and efficiency [20]. Fluoroscopy‐Guided RF Ablation in Children Traditional fluoroscopy‐guided RF ablation for pediatric AVNRT has historically shown excellent success rates, but earlier series reported mean fluoroscopy time of around 10 min [22]. With widespread adoption of 3D mapping, fluoroscopy time has fallen dramatically, often to 1 min or less [23]. Our approach eliminated fluoroscopy entirely while maintaining (or exceeding) the high success and low complication rates reported in fluoroscopy‐based studies. Zero Fluoroscopy RF Ablation in Children Several prior single‐center studies have specifically evaluated zero‐ or minimal‐fluoroscopy RF catheter ablation for SVT, including AVNRT, in pediatric patients. Topalović et al. reported zero‐fluoroscopy catheter ablation of SVT in a pediatric cohort using 3D EAM guidance, demonstrating high acute success and a favorable safety profile [11]. Chuang et al. performed a comparative study of non‐fluoroscopic versus fluoroscopic RF ablation for pediatric AVNRT, confirming that fluoroless approaches yielded equivalent procedural characteristics and ablation outcomes [12]. Our cohort, the largest reported to date of purely fluoroscopy‐free RF slow‐pathway modification in this age group, extends these findings to 125 consecutive patients and provides the longest median follow‐up of 36 months, with no documented recurrences. Taken together, the cumulative pediatric‐specific data support the feasibility, safety, and durability of zero‐fluoroscopy RF ablation for AVNRT across a range of institutional experiences. Benchmarking Against Adult Zero‐Fluoroscopy RF Data Large adult series of fluoroless AVNRT ablation have reported recurrence rates of 2.5%–3.9% with low complication rates [24, 25]. Our series demonstrates 100% acute success and zero observed recurrences, outcomes that compare favorably despite the younger age range [24]. A meta‐analysis of over 11 000 SVT ablations has demonstrated that zero or minimal‐fluoroscopy strategies achieve success and safety profiles equivalent to conventional approaches, while markedly reducing radiation exposure [8]. At centers with experience in ultrasound guided access, 3D mapping, and long sheath catheter support, fluoroless RF ablation for AVNRT can be incorporated into routine practice [10]. Energy Selection and Institutional Strategy Energy selection in AVNRT ablation should be guided by patient characteristics, operator experience, and institutional preference. In contemporary practice, RF and cryoablation are safe and effective with AVNRT [5]. RF offers procedural efficiency and may provide lower recurrence rates, making it a reasonable default strategy in adolescents and young adults when performed by experienced operators. Cryoablation is a valuable tool in very small patients (< 15 kg), in those with particularly vulnerable AV node anatomy, or when operators wish to test lesion effects before committing to a permanent ablation [2, 16, 20]. In our practice, we have adopted fluoroless RF as the primary strategy for typical AVNRT in this age group, reserving cryoablation for selected higher‐risk cases. Limitations As a single‐center retrospective study, these results reflect the outcomes of predominantly one experienced operator and team, which may not be generalized to all settings. We lacked a concurrent comparison arm of cryoablation or fluoroscopy‐guided cases. Although follow‐up was available for 94% of patients to a median duration of 36 months, some recurrences managed entirely outside our system could have been missed. Definitions of recurrence and intensity of monitoring also vary across published studies, limiting precise comparisons. Conclusions In this consecutive cohort of patients aged ≤ 21 years, zero‐fluoroscopy RF slow‐pathway modification for AVNRT was performed safely and effectively, with 100% acute success, no complications, and no recurrence observed during the extended follow‐up. At experienced centers, fluoroless RF ablation appears to be a reasonable primary strategy for AVNRT in this age group, with cryoablation reserved for selected high‐risk cases. Author Contributions Shailendra Upadhyay: concept and design; data collection; analysis and interpretation; manuscript drafting and revision; supervision. Whitney Fairchild: data and manuscript review; Jamie Bopp: data collection. Cesar Igor Mesia: analysis and interpretation; critical revision. Funding The authors have nothing to report. Ethics Statement The study was approved by our institutional IRB. Consent As a retrospective study, individual informed consent was waived. Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement The data supporting the findings of this study can be obtained from the corresponding author upon request. References Associated Data Data Availability Statement The data supporting the findings of this study can be obtained from the corresponding author upon request.